HRP20180912T1 - Makrociklički polimorfi, pripravci koji sadrže takve polimorfe, postupci proizvodnje i njihova upotreba - Google Patents

Makrociklički polimorfi, pripravci koji sadrže takve polimorfe, postupci proizvodnje i njihova upotreba

Info

Publication number
HRP20180912T1
HRP20180912T1 HRP20180912TT HRP20180912T HRP20180912T1 HR P20180912 T1 HRP20180912 T1 HR P20180912T1 HR P20180912T T HRP20180912T T HR P20180912TT HR P20180912 T HRP20180912 T HR P20180912T HR P20180912 T1 HRP20180912 T1 HR P20180912T1
Authority
HR
Croatia
Prior art keywords
polymorphs
macrocyclic
preparations containing
production procedures
procedures
Prior art date
Application number
HRP20180912TT
Other languages
English (en)
Croatian (hr)
Inventor
Yu-Hung Chiu
Tessie Mary Che
Alex Romero
Yoshi Ichikawa
Youe-Kong Shue
Original Assignee
Merck Sharp & Dohme Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38661942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20180912(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.
Publication of HRP20180912T1 publication Critical patent/HRP20180912T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
HRP20180912TT 2007-01-22 2008-01-22 Makrociklički polimorfi, pripravci koji sadrže takve polimorfe, postupci proizvodnje i njihova upotreba HRP20180912T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US88195007P 2007-01-22 2007-01-22
US11/831,886 US7378508B2 (en) 2007-01-22 2007-07-31 Polymorphic crystalline forms of tiacumicin B
EP08713185.0A EP2125850B1 (en) 2007-01-22 2008-01-22 Macrocyclic polymorphs, compositions comprising such polymorphs, methods of manufacture and use thereof
PCT/US2008/000735 WO2008091554A1 (en) 2007-01-22 2008-01-22 Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof

Publications (1)

Publication Number Publication Date
HRP20180912T1 true HRP20180912T1 (hr) 2018-07-27

Family

ID=38661942

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20180912TT HRP20180912T1 (hr) 2007-01-22 2008-01-22 Makrociklički polimorfi, pripravci koji sadrže takve polimorfe, postupci proizvodnje i njihova upotreba

Country Status (23)

Country Link
US (5) US7378508B2 (enExample)
EP (3) EP2125850B1 (enExample)
JP (2) JP5468388B2 (enExample)
KR (2) KR20150006082A (enExample)
CN (2) CN101663312B (enExample)
BR (1) BRPI0806878A2 (enExample)
CA (2) CA2676061C (enExample)
CY (1) CY1120358T1 (enExample)
DK (1) DK2125850T3 (enExample)
ES (2) ES2821384T3 (enExample)
HR (1) HRP20180912T1 (enExample)
HU (2) HUE039395T2 (enExample)
IL (2) IL199984A0 (enExample)
LT (1) LT2125850T (enExample)
MX (2) MX2009007730A (enExample)
NZ (2) NZ578697A (enExample)
PL (2) PL3412678T3 (enExample)
PT (2) PT2125850T (enExample)
RU (1) RU2478643C2 (enExample)
SI (1) SI2125850T1 (enExample)
TR (1) TR201810589T4 (enExample)
TW (2) TWI425942B (enExample)
WO (1) WO2008091554A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5113978B2 (ja) * 2003-11-21 2013-01-09 味の素株式会社 グルタミン酸誘導体の有機アミン塩及びその利用
PL2070530T3 (pl) * 2004-05-14 2016-06-30 Merck Sharp & Dohme Leczenie chorób związanych ze stosowaniem antybiotyków
US7906489B2 (en) 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
US7935377B2 (en) * 2004-06-04 2011-05-03 Ajinomoto Co., Inc. Crystals of free (2R, 4R)-monatin and use thereof
US7378508B2 (en) * 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
AU2008274941A1 (en) * 2007-07-12 2009-01-15 Tragara Pharmaceuticals, Inc. Methods and compositions for the treatment of cancer, tumors, and tumor-related disorders
TWI523654B (zh) * 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法
EA027622B1 (ru) * 2010-02-05 2017-08-31 ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "НоваМедика" Твердофазные формы макроциклических ингибиторов киназы
PE20130308A1 (es) * 2010-05-18 2013-04-06 Optimer Pharmaceuticals Inc Metodos para tratar infecciones bacterianas recurrentes
CA2826662A1 (en) * 2011-02-04 2012-08-09 Optimer Pharmaceuticals, Inc. Treatment of bacterial infections
US20150157653A1 (en) * 2012-03-16 2015-06-11 Optimer Pharmaceuticals, Inc. Prevention of Clostridium Difficile Infection in High Risk Patients
US8722863B2 (en) 2012-05-10 2014-05-13 Teva Pharmaceutical Works Ltd. Solid state forms of fidaxomycin and processes for preparation thereof
JP2015516438A (ja) * 2012-05-10 2015-06-11 テヴァ・ファーマシューティカル・ワークス・リミテッド フィダキソマイシンの固体状形態およびその調製方法
JO3464B1 (ar) * 2013-01-15 2020-07-05 Astellas Pharma Europe Ltd التركيبات الخاصة بمركبات التياكوميسين
EP2964196A1 (en) 2013-03-08 2016-01-13 Cipla Limited Pharmaceutical compositions for rectal administration
CN103275152B (zh) * 2013-05-29 2015-11-18 华北制药集团新药研究开发有限责任公司 一种高纯度非达霉素的制备方法
CN103275153B (zh) * 2013-06-27 2016-03-23 华北制药集团新药研究开发有限责任公司 一种非达霉素晶体的制备方法
CN104560766B (zh) * 2013-10-16 2017-07-28 浙江海正药业股份有限公司 一种游动放线菌菌株及其应用
US20150141356A1 (en) * 2013-11-15 2015-05-21 Optimer Pharmaceuticals, Inc. Treatment of Clostridium Difficile Infection in High Risk Patients
US9862740B2 (en) 2014-02-25 2018-01-09 Olon S.P.A. Process for preparing novel forms of tiacumicin B
WO2015127955A1 (en) 2014-02-25 2015-09-03 Olon S.P.A. A new polymorph of tiacumicin b and process for preparation thereof
ES2668351T3 (es) 2014-03-18 2018-05-17 Xellia Pharmaceuticals Aps Nuevos polimorfos y nuevos estados sólidos de tiacumicina B
US10137141B2 (en) 2014-05-09 2018-11-27 Astellas Pharma Europe Ltd. Treatment regimen tiacumicin compound
WO2015175695A1 (en) * 2014-05-13 2015-11-19 Debrabander Jef Small molecule compounds selective against gram-negative bacterial infections
CN104098637B (zh) * 2014-07-09 2017-01-04 浙江海正药业股份有限公司 一种纯化非达霉素的方法
MA41689A (fr) * 2014-10-15 2017-08-22 Bioxcel Corp Prévention ou traitement de troubles du sommeil au moyen d'une formulation de dexmédétomidine
AU2016289307A1 (en) 2015-07-03 2018-01-18 Astellas Pharma Europe Ltd. Novel dosage regimen tiacumicin compound
CN112190589A (zh) * 2020-11-17 2021-01-08 首都医科大学附属北京胸科医院 非达霉素在制备抑制鸟分枝杆菌活性的产品中的应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1458512A (en) * 1973-11-22 1976-12-15 Lepetit Spa Antibiotic substance
US4321362A (en) * 1980-06-12 1982-03-23 Eli Lilly And Company De(mycinosyloxy)tylosin and process for its production
US4918174A (en) 1986-09-26 1990-04-17 Abbott Laboratories Tiacumicin compounds
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
US5583115A (en) 1995-05-09 1996-12-10 Abbott Laboratories Dialkyltiacumicin compounds
US5767096A (en) 1996-07-12 1998-06-16 Abbott Laboratories Bromotiacumicin compounds
JP2000072760A (ja) 1998-06-19 2000-03-07 Ajinomoto Co Inc 新規シストチアゾール類縁体
JP2000053514A (ja) 1998-08-06 2000-02-22 Aquas Corp レジオネラ属細菌が生産する殺菌性物質、これを用いた殺菌剤、水処理剤、スライム抑制剤、及びこれらの製造方法
JP2000239266A (ja) 1999-02-17 2000-09-05 Ajinomoto Co Inc 新規ポリエン系抗生物質
DK1652926T3 (da) 2000-04-28 2010-02-15 Kosan Biosciences Inc Krystallinsk epothilon D
AU2001211213A1 (en) 2000-10-20 2002-04-29 Galephar M/F Stable oral formulation containing benzimidazole derivative
CA2494742C (en) * 2002-07-29 2015-05-12 Optimer Pharmaceuticals, Inc. Tiacumicin production
US20070105791A1 (en) 2002-07-29 2007-05-10 Optimer Pharmaceuticals, Inc. Method of treating clostridium difficile-associated diarrhea
US7906489B2 (en) 2004-05-14 2011-03-15 Optimer Pharmaceuticals, Inc. 18-membered macrocycles and analogs thereof
PL2070530T3 (pl) * 2004-05-14 2016-06-30 Merck Sharp & Dohme Leczenie chorób związanych ze stosowaniem antybiotyków
MX2007009196A (es) 2005-01-31 2009-02-25 Optimer Pharmaceuticals Inc Compuestos macrocilicos de 18 miembros y analogos de los mismos.
US7378508B2 (en) 2007-01-22 2008-05-27 Optimer Pharmaceuticals, Inc. Polymorphic crystalline forms of tiacumicin B
JP2009512691A (ja) 2005-10-21 2009-03-26 オプティマー ファーマシューティカルズ，インコーポレーテッド クロストリジウムディフィシレ関連の下痢の治療方法
US20080176927A1 (en) 2007-01-19 2008-07-24 Optimer Pharmaceuticals, Inc. Compositions of stable tiacumicins
ZA200905337B (en) 2007-01-22 2010-10-27 Optimer Pharmaceuticals Inc Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof
TWI523654B (zh) 2007-11-27 2016-03-01 默沙東藥廠 抗生素巨環化合物以及其製造及使用之方法

Also Published As

Publication number Publication date
EP3412678A1 (en) 2018-12-12
IL220255A0 (en) 2012-07-31
US8859510B2 (en) 2014-10-14
SI2125850T1 (en) 2018-08-31
US7863249B2 (en) 2011-01-04
PL3412678T3 (pl) 2020-12-14
TWI425942B (zh) 2014-02-11
RU2478643C2 (ru) 2013-04-10
HUE039395T2 (hu) 2018-12-28
US20070259949A1 (en) 2007-11-08
KR20150006082A (ko) 2015-01-15
CY1120358T1 (el) 2019-07-10
CA2880860A1 (en) 2008-07-31
US20090163428A1 (en) 2009-06-25
US20080194497A1 (en) 2008-08-14
MX348083B (es) 2017-05-25
US20130252914A1 (en) 2013-09-26
JP2013241440A (ja) 2013-12-05
PT2125850T (pt) 2018-07-11
KR20090117924A (ko) 2009-11-16
EP2468761A1 (en) 2012-06-27
ES2676308T3 (es) 2018-07-18
TW200840562A (en) 2008-10-16
AU2008209580A1 (en) 2008-07-31
US8883986B2 (en) 2014-11-11
CA2676061C (en) 2016-01-19
JP5764168B2 (ja) 2015-08-12
RU2009131727A (ru) 2011-02-27
TR201810589T4 (tr) 2018-08-27
EP2125850B1 (en) 2018-05-30
CA2676061A1 (en) 2008-07-31
HUE052444T2 (hu) 2021-05-28
WO2008091554A1 (en) 2008-07-31
LT2125850T (lt) 2018-08-10
DK2125850T3 (en) 2018-07-30
NZ601347A (en) 2013-11-29
PT3412678T (pt) 2020-09-29
US20100081800A1 (en) 2010-04-01
NZ578697A (en) 2012-08-31
IL199984A0 (en) 2010-04-15
JP2010516681A (ja) 2010-05-20
CN101663312A (zh) 2010-03-03
EP2125850A1 (en) 2009-12-02
EP3412678B1 (en) 2020-08-19
BRPI0806878A2 (pt) 2014-06-24
US7378508B2 (en) 2008-05-27
CN102746353A (zh) 2012-10-24
TW201350114A (zh) 2013-12-16
CN101663312B (zh) 2013-10-23
PL2125850T3 (pl) 2018-08-31
TWI453015B (zh) 2014-09-21
MX2009007730A (es) 2009-08-07
JP5468388B2 (ja) 2014-04-09
ES2821384T3 (es) 2021-04-26

Similar Documents

Publication Publication Date Title
HRP20180912T1 (hr) Makrociklički polimorfi, pripravci koji sadrže takve polimorfe, postupci proizvodnje i njihova upotreba
HRP20190378T1 (hr) Prolijekovi tetrahidrokanabinola, pripravci koji sadržavaju prolijekove tetrahidrokanabinola i postupci za njihovu uporabu
DK2479174T3 (da) 6-aminoquinazolin- eller 3-cyanquinolinderivater, fremstillingsfremgangsmåder og farmaceutiske anvendelser deraf
HUE062860T2 (hu) Magas koncentrációjú gyógyszerészeti készítmények
DE602007009504D1 (de) Ballontrokar
EP2122054A4 (en) NONWOVEN PANEL AND PRODUCTION METHOD THEREOF
BRPI1009372A2 (pt) compostos, composição farmacêutica e respectivos usos
EP2167528A4 (en) MODIFIED TOXINS
HUE049986T2 (hu) Rifaximin készítmények és ezek alkalmazásai
EP2114498A4 (en) INHALER
EP2142239A4 (en) INHALATION DEVICE
BRPI0821276A2 (pt) Produto, e, uso do produto
DK2445883T3 (da) Heterocykliske sulfonamider, anvendelser og farmaceutiske sammensætniger deraf
IL195245A0 (en) Substituted prolinamides, production thereof and their use as drugs
HUE047767T2 (hu) Macitentánt tartalmazó terápiás készítmények
BRPI0907228A2 (pt) Compostos de tienopiridazina, suas preparações, composições farmacêuticas e usos
EP2141105A4 (en) SPLICE HEAD, SPLICE DEVICE, AND SPLICE METHOD
DK2033675T3 (da) Inhalationsapparat
DK2183597T3 (da) Immunogene streptococcusproteiner
DK2182988T3 (da) Radiofarmaceutisk præparat
ATE540023T1 (de) Neuartige 3-aminoalkyl-1,3-dihydro-2h-indol-2-on- derivate, ihre herstellung und therapeutische verwendung
BRPI0814248A2 (pt) Inalador
DK2058386T3 (da) Tunnelpasteurisator
DK2240487T3 (da) Triazolopyridaziner som para-inhibitorer, fremstilling og anvendelse heraf som lægemiddel
EP2165712A4 (en) PHENOLIC EXTRACTS OF ALCOHOL SKIN CONTAINING PROCYANIDES, PROPELARGONIDINES AND PRODELPHINIDES AND METHOD FOR OBTAINING THE SAME